Aligos Therapeutics, Inc. (ALGS) vs Quince Therapeutics, Inc. (QNCX)

Aligos Therapeutics, Inc. and Quince Therapeutics, Inc. are both Biotechnology companies. Aligos Therapeutics, Inc. and Quince Therapeutics, Inc. are of similar size ($32.6M and $30.5M). Quince Therapeutics, Inc. has the higher net margin (0.00% vs −241.0%) and the higher return on invested capital (0.00% vs −3,379.3%). Across the 12 metrics below, Quince Therapeutics, Inc. leads on 8 and Aligos Therapeutics, Inc. on 4.

Valuation

Metric ALGS QNCX Biotechnology median
P/E n/m n/m 7.88
P/S 1.82 n/m 11.47
P/B 1.80 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.86 n/m 10.73
Earnings yield (132.49%) (459.06%) (28.84%)
Free cash flow yield (164.46%) (24.87%) (23.03%)

Profitability

Metric ALGS QNCX Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (250.63%) 0.00% 0.00%
Net margin (241.01%) 0.00% 0.00%
Free cash flow margin (299.90%) 0.00% 0.00%
Return on equity (113.59%) 784.09% (57.72%)
Return on assets (75.57%) (76.68%) (49.22%)
Return on invested capital (3,379.28%) 0.00% 0.00%

Growth

Metric ALGS QNCX Biotechnology median
Revenue growth (TTM) 893.01% — 5.64%
EPS growth (last fiscal year) 88.30% (28.24%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALGS QNCX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.19 14.52 4.73
Net debt to EBITDA 0.87 0.00 0.96

Dividend

Metric ALGS QNCX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ALGS QNCX Biotechnology median
Market cap 32.60m 30.51m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack